Molecular Diversity, Год журнала: 2024, Номер unknown
Опубликована: Окт. 22, 2024
Язык: Английский
European Journal of Medicinal Chemistry, Год журнала: 2025, Номер 287, С. 117367 - 117367
Опубликована: Фев. 5, 2025
Язык: Английский
Процитировано
2
Acta Pharmacologica Sinica, Год журнала: 2025, Номер unknown
Опубликована: Фев. 12, 2025
Язык: Английский
Процитировано
0
Journal of Hematology & Oncology, Год журнала: 2025, Номер 18(1)
Опубликована: Фев. 19, 2025
In the present era, noncoding RNAs (ncRNAs) have become a subject of considerable scientific interest, with peptides encoded by ncRNAs representing particularly promising avenue investigation. The identification ncRNA-encoded in human cancers is increasing. These regulate cancer progression through multiple molecular mechanisms. Here, we delineate patterns diverse and provide synopsis methodologies employed for that possess capacity to encode these peptides. Furthermore, discuss impacts on biological behavior cells underlying conclusion, describe prospects challenges need be overcome.
Язык: Английский
Процитировано
0
International Journal of Biological Sciences, Год журнала: 2025, Номер 21(4), С. 1784 - 1800
Опубликована: Фев. 10, 2025
Background: While a role for the E3 ubiquitin ligase MAEA (macrophage erythroblast attacher) has been reported in several cancer types, its importance and mechanistic functions gastrointestinal (GIC) have yet to be established. Methods: The of GIC were explored through vitro vivo experiments, including loss- gain-of-function analyses. Mass spectrometry was used identify proteins that interact with MAEA. mechanisms which influences tumor aggression examined immunoprecipitation Results: patients exhibiting reduced expression found exhibit worse disease-free overall survival outcomes. impair proliferation chemoresistance tumors subcutaneous xenograft model systems. combination PARP1 inhibitor veliparib resulted enhanced oxaliplatin treatment efficacy vivo. From perspective, mediate K48-linked ubiquitination degradation PARP1, addition suppressing M2 polarization macrophages enhancing macrophage phagocytic activity. Conclusions: These data suggest offers value as prognostic biomarker target owing ability degrade augment activity macrophages.
Язык: Английский
Процитировано
0
Molecular Pharmaceutics, Год журнала: 2025, Номер unknown
Опубликована: Янв. 8, 2025
As an enzyme that plays important role in DNA repair, poly(ADP-ribose) polymerase-1 (PARP-1) has become a popular target for cancer therapy. Nuclear medicine molecular imaging technology, supplemented by radiolabeled PARP-1 inhibitors, can accurately determine the expression level of at lesion sites to help patients choose appropriate treatment plan. In this work, niraparib was modified with hydrazinonicotinamide (HYNIC) group generate ligand NPBHYNIC, which vitro affinity (IC50) 450.90 nM PARP-1. The NPBHYNIC labeled technetium-99m and six different coligands yield [99mTc]Tc-(X/tricine)-NPBHYNIC (X = TPPTS, TPPMS, PSA, PDA, NIC ISONIC). These complexes were hydrophilic exhibited good stability vitro, low levels these taken up nontarget organs tissues Kunming mice. Among complexes, [99mTc]Tc-(TPPTS/tricine)-NPBHYNIC [99mTc]Tc-(NIC/tricine)-NPBHYNIC selected biodistribution HeLa tumor-bearing BALB/c nude mice 2 h post injection. results revealed tumor uptake (1.02 ± 0.07% ID/g) greater than (0.36 0.05% ID/g). Additionally, biodistribution, single-photon emission computed tomography/computed tomography (SPECT/CT) radioautography experiments, significantly reduced blocked group, indicating specificity. Therefore, it potential use as niraparib-based agent targets
Язык: Английский
Процитировано
0
Bioorganic & Medicinal Chemistry Letters, Год журнала: 2025, Номер unknown, С. 130167 - 130167
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Bioorganic & Medicinal Chemistry, Год журнала: 2025, Номер unknown, С. 118173 - 118173
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Journal of Medicinal Chemistry, Год журнала: 2024, Номер 68(1), С. 18 - 48
Опубликована: Дек. 26, 2024
PARP (poly-ADP ribose polymerase) has received widespread attention in cancer treatment. Research shown that plays a crucial role DNA damage repair and become popular target for drug design. Based on the mechanism of "synthetic lethality", multiple PARPis (PARP inhibitors) have been launched treatment BRCA deficient tumors. For example, approved significant potential treatment, particularly breast cancers associated with BRCA1/BRCA2 deficiencies. However, clinical efficacy safety inhibitors different remain issues cannot be overlooked. The design aims to eliminate their resistance broaden application scope. Designing selective PARP-1 is also strategy. PROTACs (Proteolysis Targeting Chimeras) degrade novel
Язык: Английский
Процитировано
1
Bioorganic & Medicinal Chemistry, Год журнала: 2024, Номер 113, С. 117936 - 117936
Опубликована: Окт. 5, 2024
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2024, Номер 16(20), С. 3447 - 3447
Опубликована: Окт. 11, 2024
Limited data are available regarding the anticancer activity of PARP inhibitors (PARPis) in pancreatic cancer with mutations HRR genes other than
Язык: Английский
Процитировано
0